News | April 19, 2023
Multiple sclerosis market to generate sales of $29.8 billion by 2030, forecasts GlobalData
Several late-stage pipeline products have the potential to address some of these unmet needs
Several late-stage pipeline products have the potential to address some of these unmet needs
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
Bourgoin early development hub broadens offerings for oral solid dose formulations
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
The facility is over 79,000 square feet and is equipped with packaging lines
Subscribe To Our Newsletter & Stay Updated
